Document |
Document Title |
WO/2024/097927A1 |
A process for regenerating a deactivated catalyst for preparing 6-aminocapronitrile, the process comprising contacting a deactivated aluminosilicate zeolite catalyst comprising a nitrogen-containing contaminant with an oxidant to provide...
|
WO/2024/097931A1 |
A process for converting caprolactam to aminocapronitrile (ACN), the process comprising contacting a caprolactam feed stream with ammonia to produce a first crude product stream; separating the first crude product stream to produce an in...
|
WO/2024/090544A1 |
The purpose of the present invention is to provide a methacrylate–containing composition that has high quality stability during storage. The methacrylate-containing composition according to one example contains methacrylate, a compou...
|
WO/2024/087613A1 |
Provided in the present invention are a preparation method for an intermediate compound used for preparing a heptafluoroisopropyl-containing bisamide compound, and a preparation method for the heptafluoroisopropyl-containing bisamide com...
|
WO/2024/089421A1 |
The invention relates to compounds of formula (I) and related aspects.
|
WO/2024/081857A1 |
A process for converting caprolactam to aminocapronitrile, the process comprising contacting a caprolactam feed with ammonia and an aluminosilicate zeolite catalyst to produce an aminocapronitrile product, wherein the catalyst comprises ...
|
WO/2024/074779A1 |
The present invention relates to a method for granulating an azo compound, comprising the following steps: a) a step of granulating by agitating an aqueous suspension of said azo compound, in the presence of an organic binder; b) an opti...
|
WO/2024/071392A1 |
This fluorine-containing ether compound is represented by the following formula. R1-CH2-R2(-CH2-R3-CH2-R2)x-CH2-R4 (In the formula, x represents an integer of 1 or 2; R2 represents a perfluoropolyether chain; R3 is represented by formula...
|
WO/2024/073383A1 |
Disclosed herein are substituted compounds of formula (I), salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.
|
WO/2024/071399A1 |
This fluorine-containing ether compound is represented by the following formula. R1-CH2-R2[-CH2-R3-CH2-R2]x-CH2-R4 (x is 1 or 2. R2 is a perfluoropolyether chain. R3 is represented by formula (2). R1 and R4 are terminal groups having 1-5...
|
WO/2024/061348A1 |
The present invention provides a 1,3-cyclohexanedione compound shown in formula I, and a stereoisomer and an agrochemically acceptable salt thereof, wherein R1, R2, R3, and R4 are as defined in the description. Also disclosed are a prepa...
|
WO/2024/061523A1 |
The present invention relates to an electroluminescent device comprising a radialene of formula (I) and an arylamine compound, diarylamine compound, triarylamine compound or a compound of formula (II), and a display device comprising the...
|
WO/2024/056678A1 |
The present invention relates to compounds according to formula (I), which are prodrugs of the psychoactive compound phenethylamine or its derivatives. The prodrugs provided herein exhibit improved pharmacokinetic properties during uptak...
|
WO/2024/046605A1 |
The compounds of formula (IA) or formula (IB) or a salt thereof. The compounds can be used as reference products in the determination of the administration of ligandrol to a subject.
|
WO/2024/045034A1 |
Disclosed in the present invention is a method for dehydrogenation esterification of an aryl phenol and an aromatic aldehyde by means of a light/nickel dual-catalysis system in the absence of an oxidant and an external photosensitizer. S...
|
WO/2024/038436A1 |
The present invention relates to the preparation of cyantraniliprole, comprising the preparation of 8-methyl-2,4-dioxo-l,4-dihydro-2H-benzo[d][l,3]oxazine-6-car
bonitrile key intermediate via 2-amino-5-((hydroxyimino)methyl)-3-methylbenz...
|
WO/2024/029481A1 |
Provided is an anti-HBV agent comprising a compound represented by formula (I) or a salt thereof. [In the formula, R1 is a phenyl group substituted with a group represented by -CN or R3-NH-CO- and an alkyl group having 1-6 carbon atoms, ...
|
WO/2024/028717A1 |
A ligand which contains arsenic and has the formula (I): where n is 2 and the ligand is bidentate; each X is O or NH; and Ar1 and Ar2 may be the same or different and each is an aryl group, provided that each Ar1 group connected to the s...
|
WO/2024/030736A1 |
Processes and facilities for producing several types of recycled content organic chemical compounds from waste plastic. Processing schemes are described herein for converting waste plastic (or hydrocarbon having recycled content derived ...
|
WO/2024/028716A1 |
A process for the hydrocyanation of an organic compound containing at least one olefinic group comprising reacting the organic compound with hydrogen cyanide in the presence of a catalyst complex comprising at least one transition metal ...
|
WO/2024/030674A1 |
Disclosed herein is a microcavity comprising a photoluminescent material positioned between two reflectors, wherein the photoluminescent material comprises a cationic molecular dye, a macrocyclic anion receptor host, and an anion embedde...
|
WO/2024/028715A1 |
A process for the hydrocyanation of an organic compound containing at least one olefinic group comprising reacting the organic compound with hydrogen cyanide in the presence of a catalyst complex comprising at least one transition metal ...
|
WO/2024/024973A1 |
A method for producing a catalyst that is used in a vapor-phase contact ammoxidation reaction, wherein: the catalyst is such that a metal oxide containing at least Mo and Sb is carried on a silica support; the method includes a sintering...
|
WO/2024/024781A1 |
This fluorine-containing ether compound is represented by the following formula. R1-CH2-R2[-CH2-R3-CH2-R2]x-CH2-R4 (x represents an integer of 1 or 2, R2 represents a perfluoropolyether chain, at least one of the x-number of R3 is repres...
|
WO/2024/024766A1 |
The purpose of the present invention is to provide an alkylating agent that can alkylate a hydroxyl group at 2' position of a synthetic intermediate for an amidite compound in the presence of a base. The present invention provides an alk...
|
WO/2024/022491A1 |
Provided are a compound of Formula (I) as an FTO inhibitor with improved and selective FTO inhibition, a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, c...
|
WO/2024/014325A1 |
An aromatic compound configured from a stable isotope, wherein two adjacent carbon atoms are 13C, the nuclear spin quantum number of the other atoms to which the two adjacent carbon atoms bond is 0, and a hydrogen atom that has a spin co...
|
WO/2024/005520A1 |
The present invention relates to intestine-specific partial agonists of farnesoid X receptor (FXR), methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compou...
|
WO/2024/000734A1 |
A mesoporous nickel powder and a preparation method therefor, and a nickel-phosphorus catalyst system. The mesoporous nickel powder comprises powder-like particles of metallic nickel, the average particle size of the particles being 1-10...
|
WO/2023/247598A1 |
The present invention relates to a compound represented by the following formula (I): [(A)n-B1]m(X)x[B2-(C)n']m' (I), wherein X is a radical derived from an aryl, a heteroaryl, a polyol, a saccharide, an amino-acid, a peptide, or a polya...
|
WO/2023/243522A1 |
The purpose of the present invention is to provide a method for producing an aromatic compound, wherein a cross-coupling reaction by means of a mechanochemical process is carried out in a state where a solvent is not substantially contai...
|
WO/2023/242106A1 |
The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders inflammatory diseases and/or genetic disorders. The present invention r...
|
WO/2023/240791A1 |
Disclosed in the present invention is an environment-friendly preparation method for an N-methylamide compound. An LED lamp is used as a light source to provide energy, an economical and easily available tertiary amide is used as a react...
|
WO/2023/232948A1 |
The present invention concerns a compound of formula (I), wherein R1 is H or an organic moiety, said compound of formula (I) having a biocarbon content equal to or higher than 20%.
|
WO/2023/221851A1 |
Provided is a method for preparing valproamide represented by chemical structural formula I and sodium valproate represented by formula II. The method is characterized in that cyanoacetate and 1-chloropropane are subjected to composite c...
|
WO/2023/224095A1 |
This fluorine-containing ether compound is represented by the following formula. R1-R2-CH2-R3[-CH2-R4-CH2-R3]x-CH2-R5-R6 (where R1 and R6 are organic groups having 1-50 carbon atoms, R2 is formula (2-1) or (2-2), R5 is formula (2-3) or (...
|
WO/2023/224093A1 |
This fluorine-containing ether compound is represented by the following formula. R1-CH2-R2[-CH2-R3-CH2-R2]x-CH2-R4 (Where: R1 and R4 are terminal groups which include 2 or 3 polar groups, in which each polar group bonds to a different ca...
|
WO/2023/218970A1 |
Provided are, inter alia, an active-ray-sensitive or radiation-sensitive resin composition containing a resin that increases in polarity under the action of acid and a compound having a specified structure, an active-ray-sensitive or rad...
|
WO/2023/216063A1 |
The present invention provides a method for preparing a 2-substituted aryl acetonitrile compound and use thereof. The method prepares the 2-substituted aryl acetonitrile compound by means of a direct reaction under the action of a base w...
|
WO/2023/219521A1 |
The invention relates to novel 2-(diethylamino)-4,6-diphenylbenzene-1,3-carbonitrile derivatives of general formula (1) in which R1 stands for: one of the following groups, where the dashed line indicates a bond that is, the compounds se...
|
WO/2023/213381A1 |
Suggested is at least one compound of Formula I.
|
WO/2023/207002A1 |
Provided in the present invention is a vanadium-boron catalyst, which is obtained by dissolving a vanadium compound, a phosphorus compound and a boron compound in a solution, adding an auxiliary metal element compound thereto to form a c...
|
WO/2023/202377A1 |
The present application provides a deuterated composition, an organic electroluminescent device, and a display apparatus. The deuterated composition comprises a deuterated mixture prepared from compound A by means of a deuteration reacti...
|
WO/2023/203254A2 |
The present invention relates to compounds inhibiting the toxic activity of extrasynaptic NMDA receptors, in particular by inhibiting the formation of NMDA receptor/TRPM4 complexes. In particular, the present invention relates to diamine...
|
WO/2023/170657A1 |
The present disclosure relates to improved processes to recover acetonitrile from aqueous and organic waste streams, particularly those generated during oligonucleotide manufacturing processes.
|
WO/2023/167325A1 |
The present invention addresses the problem of developing a metal catalyst which is suitable for continuous flow organic synthesis reaction, is excellent in durability, and has high activity. The present invention provides an immobiliz...
|
WO/2023/160035A1 |
A β-elemene vinylation coupled derivative, and a preparation method therefor and the use thereof in the preparation of an antitumor drug. Provided are a β-elemene vinylation coupled derivative having a structure as represented by formu...
|
WO/2023/160316A1 |
Disclosed are a pyrethroid compound containing double bonds and cyano groups, a synthesis method therefor and an application thereof. In the synthesis method, 3-formyl-2,2-dimethyl-cyclopropanoate t-butyl ester and cyanomethylphosphonate...
|
WO/2023/163067A1 |
A catalyst containing: metal oxides, which are oxides of metals including molybdenum, bismuth and iron; and silica for supporting the metal oxides, wherein A/B is 0.95 to 1.04 where A is a silicon surface parameter based on SEM-EDX, and ...
|
WO/2023/159303A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula I or Formula II and compositions thereof for use in the treatment of cancer. In particular, the Myc- Max inhibitory compounds may be useful for the treatmen...
|